Edition:
United States

Medtronic PLC (MDT)

MDT on New York Consolidated

83.09USD
28 Apr 2017
Change (% chg)

$-0.04 (-0.05%)
Prev Close
$83.13
Open
$83.04
Day's High
$83.11
Day's Low
$82.66
Volume
3,915,398
Avg. Vol
5,022,467
52-wk High
$89.27
52-wk Low
$69.35

MDT

Chart for MDT

About

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group,... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $113,740.70
Shares Outstanding(Mil.): 1,368.89
Dividend: 0.43
Yield (%): 2.07

Financials

  MDT Industry Sector
P/E (TTM): 29.32 35.26 30.08
EPS (TTM): 2.83 -- --
ROI: 4.42 12.59 13.25
ROE: 7.92 14.63 14.41

BRIEF-Medtronic expands pain therapies portfolio with the launch of Osteocool RF ablation system

* Medtronic expands pain therapies portfolio with the launch of Osteocool RF ablation system Source text for Eikon: Further company coverage:

Apr 27 2017

Global foundation launches value-based healthcare pilots

Key healthcare stakeholders, led by the World Economic Forum, plan pilot programs this year to show the value of a new model for healthcare that would track and pay for treatment based on how well it works rather than the volume of care.

Apr 26 2017

Global foundation launches value-based healthcare pilots

April 26 Key healthcare stakeholders, led by the World Economic Forum, plan pilot programs this year to show the value of a new model for healthcare that would track and pay for treatment based on how well it works rather than the volume of care.

Apr 26 2017

BRIEF-Medtronic announces outcomes from VeClose clinical trial, ‍WAVES study​

* New Medtronic data demonstrate clinical and quality of life benefits for VenaSeal closure system in venous reflux disease patients

Apr 25 2017

BRIEF-Medtronic drug-coated balloon demonstrates consistent results

* Medtronic drug-coated balloon (DCB) demonstrates consistent results in two new analyses of complex pad patients

Apr 25 2017

Lackluster $24 bln medical merger better than none

NEW YORK (Reuters Breakingviews) - Obamacare lives on. Republican U.S. lawmakers haven't yet repealed the Affordable Care Act, as it's formally known. Healthcare companies have to live with it, too. Becton Dickinson's $24 billion deal to buy C.R. Bard is one result. The expected cost savings fall well short of justifying the 25 percent premium. But scale brings needed negotiating power selling needles and catheters to hospitals.

Apr 24 2017

Becton Dickinson to acquire Bard for $24 billion

NEW YORK U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday. | Video

Apr 24 2017

UPDATE 3-Becton Dickinson to acquire Bard for $24 billion

NEW YORK, April 23 U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday.

Apr 23 2017

LPC: US healthcare lending rouses from policy-induced sedation

NEW YORK US drug distributor Cardinal Health Inc’s deal to buy Medtronic Plc’s medical supplies units days after Abbott Laboratories agreed to a long-awaited purchase of diagnostic testing company Alere Inc has raised the pulse of a sector suppressed by potential healthcare policy upheaval.

Apr 20 2017

LPC: U.S. healthcare lending rouses from policy-induced sedation

NEW YORK U.S. drug distributor Cardinal Health Inc’s deal to buy Medtronic Plc’s medical supplies units days after Abbott Laboratories agreed to a long-awaited purchase of diagnostic testing company Alere Inc has raised the pulse of a sector suppressed by potential healthcare policy upheaval.

Apr 20 2017

More From Around the Web

Earnings vs. Estimates